PT  - JOURNAL ARTICLE
AU  - Hoyle, Brian
ED  - Eichhorst, Barbara
TI  - FCR Superior in Treatment of Advanced CLL
DP  - 2014  01
TA  - MD Conference Express
PG  - 16--16
VI  - 14
IP  - 55
4099  - http://mdc.sagepub.com/content/14/55/16.1.short
4100  - http://mdc.sagepub.com/content/14/55/16.1.full
AB  - Bendamustine plus rituximab is inferior to fludarabine plus cyclophosphamide plus rituximab in treatment of chronic lymphocytic leukemia. The triple-drug combination is associated with improved outcomes but higher rates of neutropenia and severe infection. The triple combination remains the standard therapy in fit patients, with the double combination being an option for elderly patients.